GHRL and metabolic dysfunction-associated steatohepatitis: NASH group: higher prevalence of SIBO (50% vs. 9.1%; p = 0.025; lower plasma levels of acylated ghrelin (p = 0.015); higher fasting insulin concentrations (p < 0.006).